



# Endometrial Cancer Committee Agenda Chicago May 30, 2014



Ketta Lorusso, Stefano Greggi

## **1. Endometrial cancer Conservative Treatment 2 trials Ready to start**

**a) Conservative treatment of endometrial cancer:  
a multicentre registry study (ECCO trial)**

**Dr Greggi**

**b) feMME Trial: A Phase II Randomised Clinical  
Trial of Mirena® ± Metformin ± Weight Loss  
Intervention in Patients with Early Stage Cancer  
of the Endometrium**

**Dr Obermair**

## 2. Endometrial staging: 2 trials

a) KGOG 2015:

**Multicenter prospective observational study for the validation of preoperative low-risk criteria for lymph node metastasis in endometrial cancer. 514/514**

Dr Kang

b) GOG 0233/ACRIN 6671:

**Preoperative FDG-PET/CT to Detect Lymph Node Metastasis. CLOSED**

## GCIG STUDIES FOR BRIEF UPDATE AND FU

### 3. Surgery: 1 trial Ready to start

- **Lymphadenectomy STATEC Trial: Selective  
Targeting of Adjuvant Therapy for Endometrial  
Cancer-**

**Dr Mould**

## **4. Endometrial adjuvant: 6 trials**

### **a) ENGOT-EN2-DGCG:**

**A phase III trial of postoperative chemotherapy or no further treatment for patients with node negative stage I-II intermediate or high risk endometrial cancer. 39/678**

**Interested groups: AGO, BGOG, EORTC, MANGO**

**Dr Mirza**

# Endometrial: Stage I/II Adjuvant

## GOG 0249

### Eligible:

- Stage I\* endometrioid-type endometrial carcinoma, with high-intermediate risk factors with (+) or without (-) cytology
- Stage II\* endometrial carcinoma (any histology), with or without risk factors
- Stage I-II\* serous or clear cell endometrial carcinoma with negative cytology, with or without other risk features

R  
A  
N  
D  
O  
M  
I  
Z  
E

### Regimen I:

- Pelvic Radiation Therapy (4500/25 fractions-5040 cGy/28 fractions) over 5-6 weeks
- Optional Vaginal Cuff Boost ONLY for Stage II patients and Stage I patients with papillary serous and clear cell carcinomas

### Regimen II:

- Vaginal Cuff Brachytherapy + 3 cycles of chemotherapy\* consisting of:
  - Paclitaxel 175 mg/m<sup>2</sup> (3hr) + Carboplatin AUC 6 q 21 days

\*To start within 3 weeks of initiating brachytherapy

\* FIGO 2009 Staging Criteria

- 3/23/2009 – 2/4/2013 **Completed**
- Endorsed by RTOG
- 562 accrued

## 4. Endometrial adjuvant

### b) PORTEC 3:

**Randomized phase III trial comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with pelvic Radiation Alone in High Risk and Advanced Endometrial Carcinoma . 680/680**

**Participating groups: NCRI, MaNGO, ANZGOG, NCIC-CTG. NSGO interestd.**

**Dr Creutzberg**

## **4. Endometrial adjuvant**

### **c) PORTEC 4:**

**Randomized trial of vaginal  
brachytherapy vs observation for  
high-intermediate risk  
endometrial carcinoma. 38/500**

**Dr Creutzberg**



## **3. Endometrial adjuvant**

### **a) TIME-C STUDY:**

**A Randomized phase III study of standard vs IMRT pelvic radiation for post-operative treatment of endometrial and cervical cancer**

**Participating groups: RTOG**

**David Gaffney**

## 4. Endometrial adjuvant

### d) GOG-0258

A randomized phase III trial of Cisplatin and Tumor Directed RT followed by Carboplatin/Paclitaxel vs Carboplatin/Paclitaxel for optimally debulked advanced endometrial cancer: **773/804**

Participating group: RTOG

Dr Miller

## **4. Endometrial follow up: 1 trial**

### **a) APPROPRIATENESS EVALUATION OF FOLLOW UP PROCEDURES IN GYNECOLOGY ONCOLOGY TOTEM STUDY:**

**Multicentric randomized controlled clinical trial between two follow up regimens with different tests intensity in endometrial cancer treated patients. 1064/2300**

Dr Zola

## **5. Endometrial advanced/recurrent: 3 trials**

### **a) GOG-0238**

**A randomized trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus. 78/154**

**Participating Group: RTOG**

**Dr Miller**

## **5. Endometrial advanced/recurrent**

### **b) MITO BEVA END TRIAL:**

**Randomized phase II trial on  
Carboplatin-Paclitaxel compared to  
Carboplatin-Paclitaxel-Bevacizumab in  
patients with advanced (stage III-IV) or  
recurrent endometrial cancer. 88/108**

**Participating Group: MITO-MaNGO**

**Dr Lorusso**

## **5. Endometrial advanced/recurrent**

**c) NSGO:**

**A Randomized phase II trial of first line combination chemotherapy with BIBF1120/placebo in patients with advanced or recurrent endometrial cancer. Ready to start**

**Interested Group: MaNGO**

**Dr Mirza**

## **6. Rare Endometrial cancer/clear cell**

### **a) Endometrial Clear Cell:**

**Randomized phase II study on BIBF 1120 compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. **Ready to start****

**Participating Group: SGCTG, NSGO, EORTC, GINECO**

**Dr Glasspool**

## **6. Rare Endometrial cancer/ uterine leiomyosarcoma 2 trials**

### **b) GOG 0277 (UC1009)**

**A Randomized Phase III trial of  
Gemcitabine plus Docetaxel followed  
by Doxorubicin vs Observation for  
Uterus-Limited, High Grade Uterine  
Leiomyosarcoma. 10/216**

**Interested group: EORTC**

**Dr Hensley**



## **6. Endometrial cancer/ uterine leiomyosarcoma**

### **c) GOG 0250**

**A Randomized Phase III trial of  
Gemcitabine plus Docetaxel with or  
without Bevacizumab in advanced,  
High Grade Uterine Leiomyosarcoma.**

**107/107 (closed)**

**Presented SGO 2014**

## **6. Rare Endometrial cancer/high grade undifferentiated uterine sarcoma 1 trial**

**d) EORTC 62113-55115/ GOG UC 1306**

**Cabozantinib maintenance in high grade, undifferentiated uterine sarcoma. 0/78**

## **6. Rare Endometrial cancer/carcinosarcoma 1 trial**

### **e) GOG 261**

**Randomized phase III trial on  
Carboplatin-Paclitaxel vs Paclitaxel-  
Ifosfamide in the treatment of stage I-  
IV chemonaive uterine  
carcinosarcoma. 637/637, CLOSED**

**Dr Miller**

## **7. Endometrial cancer/ Trophoblastic Neoplasia: 3 TRIALS**

### **a) GOG-0242**

**A phase II study to determine the response to Second Curettage as Initial Management of persistent, low risk, non metastatic Gestational Trophoblastic Neoplasia. 64/64 (closed)**

**Dr Schink**

## **7. Endometrial cancer/ Trophoblastic Neoplasia**

### **b) GOG 0275 (UC 1005):**

**A phase III randomized trial of Pulse Actinomycin-D vs Multi-Day Methotrexate for the treatment of low risk Gestational Trophoblastic Neoplasia. 21/381**

**Dr Schink**

## **7. Endometrial cancer/ Trophoblastic Neoplasia: ready to start**

### **c) High Risk GTD:**

**A randomized phase II trial comparing the toxicity of Paclitaxel-Etoposide (TE) alternating two weekly with Paclitaxel-Cisplatin (TP) with Etoposide and Cisplatin (EP) alternating weekly with Etoposide, Metotrexate and Dactinomycin (EMA) in GTN patients failing non platinum-based combination agent therapies.**

**Dr Seckl**

## **Endometrial Cancer Challenging Debate**

**What is the most appropriate  
treatment in high intermediate  
and high risk endometrial  
cancer?**

**Thank you!!!**

**See you in Melbourne (November 2014)**

